Therefore, endothelial activation biomarkers, including vWF, Ang-2, and endothelial-stabilizing biomarkers, such as Ang-1, and should be monitored before and after CAR-T cell infusion to monitor the incidence of CRS and ICANS. Here, ANGPT2 is linked to congenital rubella syndrome.